CAPR

Capricor Therapeutics (CAPR) P/E Ratio
P/E Ratio as of Oct 29, 2026: -2.71
Average-2.93
Median-2.78
Minimum-3.87
Maximum-2.34
-2.71
0.79 (22.57%)past month
The P/E ratio for Capricor Therapeutics (CAPR) is -2.71 as of Oct 29, 2026. This represents a decrease of -70.38% compared to its 12-month average P/E ratio of -9.15. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Capricor Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Capricor Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Capricor Therapeutics to industry peers.
Capricor Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Capricor Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Capricor Therapeutics to industry peers.
Capricor Therapeutics (CAPR) P/E Ratio Insights
See Capricor Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares
Capricor Therapeutics (CAPR) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Oct 1, 2026 | $8.94 | -3.65 |
| Sep 1, 2026 | $10.01 | -4.09 |
| Aug 3, 2026 | $4.20 | -1.82 |
| Jul 1, 2026 | $23.07 | -9.97 |
| Jun 1, 2026 | $28.53 | -12.34 |
| May 1, 2026 | $30.91 | -13.70 |
| Apr 1, 2026 | $30.12 | -13.35 |
| Mar 2, 2026 | $26.86 | -14.93 |
| Feb 2, 2026 | $23.09 | -12.84 |
| Jan 2, 2026 | $28.31 | -15.74 |
Capricor Therapeutics (CAPR) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | -2.71 | -83.10% |
| 2025 | -16.04 | +23.48% |
| 2024 | -12.99 | +206.37% |
| 2023 | -4.24 | +24.34% |
| 2022 | -3.41 | +0.89% |
| 2021 | -3.38 | — |
FAQs About Capricor Therapeutics (CAPR) P/E ratio
The latest P/E ratio of Capricor Therapeutics (CAPR) is -2.71, as of Oct 29, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Capricor Therapeutics’s last 12-month average P/E ratio is -9.15, compared to its current P/E ratio of -2.71. This reflects a decrease of -70.38%.
Capricor Therapeutics’s current P/E ratio of -2.71 is lower than its last 12-month average P/E of -9.15. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Capricor Therapeutics’s average P/E ratio over the last 3 years is -8.45. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Capricor Therapeutics’s average P/E ratio over the last 5 years is -6.71. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.
Capricor Therapeutics (CAPR) P/E Ratio Insights
See Capricor Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.